110 related articles for article (PubMed ID: 17543947)
1. Racial differences in the incidence and outcomes for patients with hematological malignancies.
Flowers CR; Glover R; Lonial S; Brawley OW
Curr Probl Cancer; 2007; 31(3):182-201. PubMed ID: 17543947
[No Abstract] [Full Text] [Related]
2. Mortality trend of hematologic and lymphatic malignancy (lymphoma, multiple myeloma and leukemia) in Japan: 1960-2000.
Yoshimi I; Kaneko S
Jpn J Clin Oncol; 2004 Apr; 34(4):218-25. PubMed ID: 15190904
[No Abstract] [Full Text] [Related]
3. Mortality trends of hematologic neoplasms (lymphoma, myeloma, and leukemia) in Japan (1960-2000): with special reference to birth cohort.
Yoshimi I; Mizuno S
Jpn J Clin Oncol; 2004 Oct; 34(10):634-7. PubMed ID: 15591464
[No Abstract] [Full Text] [Related]
4. [Causes of death in hematopoietic malignancies--increasing incidences of gastrointestinal bleeding].
Sawada H; Nishikori M; Mochizuki T; Ishikura H; Izumi Y; Usui T; Konishi H; Uchino H
Rinsho Ketsueki; 1983 Feb; 24(2):119-25. PubMed ID: 6606717
[No Abstract] [Full Text] [Related]
5. [Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)].
Ohno R; Kodera Y; Ogura M; Murase T; Emi N; Okumura M; Morishita Y; Nagura E; Minami S; Morishima Y
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2531-6. PubMed ID: 6594973
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy of interferon-beta (MR-21) in hematological malignancies].
Imamura Y
Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):934-41. PubMed ID: 3694002
[No Abstract] [Full Text] [Related]
7. Geographic and secular variation in mortality from malignant disease in Oklahoma, 1956-1965.
Assal NR; Lindeman RD
J Okla State Med Assoc; 1970 Oct; 63(10):469-80. PubMed ID: 5515631
[No Abstract] [Full Text] [Related]
8. Treating the older patient with leukemia, lymphoma, and myeloma.
ONS News; 2004; 19(9 Suppl):77-8. PubMed ID: 15478599
[TBL] [Abstract][Full Text] [Related]
9. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: Hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis.
Sari I; Altuntas F; Hacioglu S; Kocyigit I; Sevinc A; Sacar S; Deniz K; Alp E; Eser B; Yildiz O; Kaynar L; Unal A; Cetin M
Am J Hematol; 2008 Apr; 83(4):334-9. PubMed ID: 18069671
[TBL] [Abstract][Full Text] [Related]
10. Leukemia in close relatives--accident or predisposition?
Gunz FW; Veale AM
J Natl Cancer Inst; 1969 Mar; 42(3):517-24. PubMed ID: 4180615
[No Abstract] [Full Text] [Related]
11. Does multiple myeloma incidence vary by geographic area?
Coleman EA; Senner JW; Edwards BK
J Ark Med Soc; 2008 Oct; 105(4):89-91. PubMed ID: 18982903
[No Abstract] [Full Text] [Related]
12. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
Gil L; Styczynski J; Komarnicki M
Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
[TBL] [Abstract][Full Text] [Related]
13. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
Rodrigues CA; Sanz G; Brunstein CG; Sanz J; Wagner JE; Renaud M; de Lima M; Cairo MS; Fürst S; Rio B; Dalley C; Carreras E; Harousseau JL; Mohty M; Taveira D; Dreger P; Sureda A; Gluckman E; Rocha V
J Clin Oncol; 2009 Jan; 27(2):256-63. PubMed ID: 19064984
[TBL] [Abstract][Full Text] [Related]
14. Battling the hematological malignancies: the 200 years' war.
Lichtman MA
Oncologist; 2008 Feb; 13(2):126-38. PubMed ID: 18305057
[TBL] [Abstract][Full Text] [Related]
15. Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994-2003.
Roswall N; Olsen A; Christensen J; Rugbjerg K; Mellemkjaer L
Eur J Cancer; 2008 Sep; 44(14):2058-73. PubMed ID: 18657412
[TBL] [Abstract][Full Text] [Related]
16. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in lung cancer.
Berger M; Lund MJ; Brawley OW
Curr Probl Cancer; 2007; 31(3):202-10. PubMed ID: 17543948
[No Abstract] [Full Text] [Related]
18. Present status and future problems of interferon in the treatment of hematological malignancies.
Kimura K
Nihon Ketsueki Gakkai Zasshi; 1985 Dec; 48(8):1677-87. PubMed ID: 2425532
[No Abstract] [Full Text] [Related]
19. Life-table calculations of excess risk for incidence versus mortality: ethylene oxide case study.
Sielken RL; Valdez-Flores C
Regul Toxicol Pharmacol; 2009 Oct; 55(1):82-9. PubMed ID: 19508882
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years.
Huang SY; Yao M; Tang JL; Lee WC; Tsay W; Cheng AL; Wang CH; Chen YC; Shen MC; Tien HF
Cancer; 2007 Aug; 110(4):896-905. PubMed ID: 17594697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
